EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells.

These data suggest that the combination of EZH2 inhibitors with EGFR-TKIs may be an effective method for treating NSCLC-patients with EGFR-wild type, who do not want to undergo traditional treatment with chemotherapy.